Fermented Probiotic Fruit Juice Reduced Colitis Flares and Boosted Gut Metabolites in Mice

A commercial fermented fruit juice containing three probiotic strains has shown early promise in protecting the intestinal lining and reducing the severity of colitis flares in mice, according to new research published on Research Square. The study, led by H. Moradian, F. Jospin, J. Guillemot, S. Paul, and colleagues, is a preprint and has not yet been peer-reviewed, so the findings should be treated as preliminary. Still, the breadth of the evidence, spanning cell cultures, animal models, microbiome sequencing, and metabolomics, makes it an unusually thorough early-stage investigation.

Probiotic Fermented Fruit Juice Protected Intestinal Barrier Integrity

The product at the center of the study is called Harmony Shot, made by Basal Nutrition. It is a juice fermented with three bacterial strains: Bifidobacterium longum SP 54, Lactobacillus paracasei IMC 502, and L. rhamnosus IMC 501. The raw ingredients, apples, carrots, and blackcurrants, come from certified organic farming. After fermentation, the juice contained more than 10^8 colony-forming units per milliliter of viable bacteria, a concentration significantly higher than the same strains simply rehydrated in water.

The researchers first tested the juice on Caco-2 cells, a standard human intestinal cell line used to model the gut barrier. When cells were exposed to lipopolysaccharide (LPS), a bacterial molecule that triggers inflammation, their trans-epithelial electrical resistance (TEER) dropped sharply. TEER is a measure of how tightly sealed the cell layer is; lower values mean a more permeable, "leaky" barrier. Co-treatment with the fermented juice restored TEER toward normal levels. It also prevented the disruption of ZO-1, a tight junction protein that acts like molecular glue holding intestinal cells together. As research on probiotics and gut immunity has noted, the precise mechanisms behind such effects remain an active area of investigation, and factors like diet and age can complicate interpretation.

Colitis Severity Dropped in Mice Pre-Treated with the Juice

The animal experiments used a dextran sodium sulfate (DSS) colitis model in C57BL/6 mice, with two sequential DSS inductions designed to mimic the relapsing-remitting pattern seen in human inflammatory bowel disease. IBD affects millions of people worldwide, encompassing conditions like Crohn's disease and ulcerative colitis, and current treatments carry significant side effects, which is why complementary strategies like dietary interventions are being actively explored.

Mice that received the fermented juice before and during DSS exposure showed meaningful protection. Body weight loss was lower, and disease activity index (DAI) scores, a composite measure incorporating stool consistency, bleeding, and weight change, were significantly reduced during the second induction cycle. That second-cycle effect is notable because it suggests the juice may help prevent subsequent flares rather than just blunting an initial insult.

Colon length also told a clear story. DSS typically causes significant shortening of the colon, a sign of inflammation-driven tissue damage. In juice-treated mice, colonic length was better preserved. Histological sections stained with hematoxylin and eosin showed that DSS destroyed normal epithelial architecture and crypt structures, while mice given the fermented juice retained far more mucosal integrity. The juice outperformed probiotics rehydrated in water (PinW) on most symptom measures, and both interventions reduced elevated interleukin-6 (IL-6), a key inflammatory cytokine, though the juice showed superior overall effects.

How the Researchers Isolated Fermentation's Role

One of the more methodologically interesting aspects of the study was a direct comparison between the fermented juice and non-fermented juice using metabolomic analysis. The two preparations showed substantially different chemical profiles, confirming that fermentation meaningfully transforms the juice's composition beyond simply adding bacteria.

The fermented juice was enriched in several bioactive compounds. Short-chain fatty acids (SCFAs), particularly butyrate, isobutyrate, and valerate, were significantly elevated in the blood of juice-treated mice. Butyrate is a primary fuel source for colonocytes and is widely recognized for its anti-inflammatory properties in the gut. The juice also raised levels of imidazole-containing compounds derived from histidine and histamine catabolism, and of muricholate, a primary bile acid. Perhaps most striking was a significant increase in acetylcholine, a neurotransmitter known for anti-inflammatory signaling that can be produced by lactic acid bacteria. These metabolic shifts point toward fermentation, not just the probiotic strains themselves, as a meaningful driver of the observed effects. This distinction matters given ongoing challenges in probiotic research, where disentangling the contributions of specific strains, their metabolites, and the surrounding food matrix remains difficult.

Gut Microbiota Shifted Toward Beneficial Strains

In healthy mice given the juice, overall gut microbiota diversity did not change dramatically, but the composition shifted in ways considered beneficial. Beta-diversity, a measure of community structure between samples, was altered. The juice enriched populations of Enterohabdus, Muribaculum, and certain Clostridium species. Muribaculum is of particular interest because it has been associated with IBD amelioration and SCFA production in prior research. Notably, Bifidobacterium longum, one of the three strains in the product, was not detected in mouse feces, possibly because of its strict anaerobic requirements or limitations in the sequencing primers used.

Open Questions Before Human Trials Can Be Designed

The study has meaningful limitations that the authors acknowledge. The in-vivo experiments and metabolomics work lacked a non-juice control group, making it hard to fully separate the contributions of the probiotic bacteria, the fermentation metabolites, and the juice base itself. The Caco-2 cell model is a monolayer that lacks immune cells and the three-dimensional architecture of the living intestinal wall. And while the DSS mouse model is widely used, translating findings from rodent colitis models to human IBD remains a recognized challenge in the field.

All of that said, the convergence of evidence across cell, animal, microbiome, and metabolite data provides a richer mechanistic picture than most early-stage studies offer. The focus on next-generation probiotic therapeutics is accelerating, with researchers increasingly looking at specific bacterial metabolites like butyrate as the active agents. This study's suggestion that the fermentation process itself amplifies those metabolites is a thread worth pulling. Human trials will be needed to know whether Harmony Shot or a similar fermented juice can replicate these effects in people with IBD, but the preclinical foundation here is more substantial than typical for a product at this stage.